Aphria (APHQF) is one of the top medical cannabis licensed producers in Canada. The stock, however, has struggled so far this year. It closed at 11.75 Canadian dollars, which was far from 20.19 Canadian dollars at the start of this year.
To see how Aphria compares with companies (HMMJ) such as Aurora Cannabis (ACB) and Canopy Growth (WEED) (CGC), read Comparing Major Cannabis Players’ Prices and Cost Structures.
Let’s see how Aphria’s ratings have changed.
As of July 4, the average consensus price target for Aphria stood at 23.91 Canadian dollars. However, the median price target was slightly higher at 25.75 Canadian dollars from 25.38 Canadian dollars a month ago.
If the current price were to converge with the price target, it would more than double the company’s value.
The company has an overall “buy” recommendation for the next 12 months. Of the eight analysts in the above chart, three have a “strong buy” for the stock, which was unchanged from the previous update. Similarly, four analysts have maintained a “buy” for the stock, and one analyst has a “hold” recommendation for the next 12-month period.
Next, we’ll look at analysts’ recommendations and price targets for Cronos Group (CRON).